Efficacy of Stable Same Tosylate Tablets to Reduce Signs of Age Related Behavior Problems in Dogs
World Small Animal Veterinary Association World Congress Proceedings, 2006
C. Rème1, V. Dramard2, L. Kern3, J. Hofmans4, C. Halsberghe5, D. Vida Mombiela6
1Medical Department Virbac SA, Carros, France; 2Veterinary Clinic, Lyon, France; 3Veterinary Clinic, Paris, France; 4Veterinary Clinic, Fléron, Belgium; 5Veterinary Clinic, Kortrijk, Belgium; 6Veterinary Centre Poble Sec, Barcelona, Spain

A double-blind placebo-controlled trial evaluated whether oral stable S-adenosylmethionine tosylate (NoviSAMeTM) supplementation (Novifit® tablets, Virbac) could be useful in the management of age-related mental decline in dogs. Thirty-six dogs over 8 years that had displayed for at least 1 month signs of cognitive dysfunction were included in the study. Exclusion criteria were incapacitating disease, hypothyroidism, and recent administration of psychotropic drugs. The dogs were administered NoviSAMeTM 18 mg/kg (n=17) or identical placebo tablets (n=19) for 2 months. Concurrent behavioural treatment was forbidden. Examinations were performed on D0, D30 and D60. A codified grid with 12 items evaluated disorientation, learning deficits, decreased awareness or activity, social interactions, altered sleep-wake cycle, inappropriate toileting and anxiety. The scores were added together to give a Standardised Geriatric Behaviour Score (SGBS). Ability of the dogs to perform 4 observable daily activities selected by owners was rated every 2 weeks to give a Case-Specific Disability Score (CSDS). Decreased purposeful activity (75% of dogs), diminished reaction upon verbal command (77.8%) and increase of the period of sleep over 24h (83.3%) were the most frequent signs on D0.Greater SGBS reduction was recorded with NoviSAMeTM than with the placebo (P=0.016 on D30, P=0.037 on D60).

Figure 1.
Figure 1.

Reduction of the geriatric behavior score.
 

Eleven (64.7%) and 7 dogs (36.8%) responded favourably to NoviSAMeTM and placebo therapy respectively. NoviSAMeTM supplementation produced clinically meaningful improvement in the level of activity (57.1%), awareness (59.5%) and elimination disorders (57.1%). NoviSAMeTM proved more effective than placebo to reduce the CSDS as scored by owners (P=0.004 on D30, P=0.013 on D60.

Figure 2.
Figure 2.

Case-specific disability score over time
 

Tolerance to the supplementation was recorded as good in 16/17 dogs. One dog exhibited transient diarrhoea. Novifit® tablets proved safe and effective to improve signs of age-related mental decline in dogs.

Speaker Information
(click the speaker's name to view other papers and abstracts submitted by this speaker)

C. Rème
Medical Department
Virbac SA
Carros, France


MAIN : Posters – Abstracts : Efficacy of Tosylate Tablets
Powered By VIN

CONTACT US

777 W. Covell Blvd., Davis, CA 95616

mailto:vingram@vin.com

PHONE

  • Toll Free: 800-700-4636
  • From UK: 01-45-222-6154
  • From anywhere: (1)-530-756-4881
  • From Australia: 02-6145-2357
SAID=27